Chimeric antigen receptors comprising BCMA-specific fibronectin type III domains and uses thereof
US11096998B2 · kind B2 · utility
0Cited by
34References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 11, 2017 |
| Grant date | Aug 24, 2021 |
| Priority date | — |
| Expiry date | Sep 11, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.